June 18th 2020, 11:45am
The combination of atezolizumab and nab-paclitaxel, followed by doxorubicin and cyclophosphamide, demonstrated a statistically significant and clinically meaningful improvement in pathological complete response compared with placebo plus chemotherapy as a neoadjuvant treatment for patients with early triple-negative breast cancer, regardless of PD-L1 expression.
June 17th 2020, 7:35pm
Nancy U. Lin, MD, discusses the updated data from the HER2CLIMB trial and underscored the need for future clinical trials that include patients with brain metastases to help fill the unmet need in the HER2-positive space.
June 16th 2020, 2:58pm
Abemaciclib in combination with standard adjuvant endocrine therapy demonstrated a significant improvement in invasive disease-free survival compared with endocrine therapy alone in patients with high-risk, HR-positive, HER2-negative early breast cancer.
June 15th 2020, 9:19pm
Stephanie L. Graff, MD, discusses future research with immunotherapy in breast cancer.
June 10th 2020, 2:10pm
The novel HER2-directed antibody-drug conjugate trastuzumab deruxtecan-nxki demonstrated promising antitumor activity in patients with heavily pretreated, HER2 low-expressing advanced or metastatic breast cancer.
June 10th 2020, 6:29am
Join us for a live broadcast on Wednesday, June 17, 2020 at 5 PM PST and 8 PM PST.
June 9th 2020, 10:34pm
Javier Cortes, MD, PhD, discusses updated progression-free survival data from the phase 3 KEYNOTE-355 study with pembrolizumab plus chemotherapy in previously untreated patients with locally recurrent, inoperable or metastatic triple-negative breast cancer.
June 9th 2020, 9:43pm
Sara M. Tolaney, MD, MPH, discusses the unmet need with regard to effectively preventing central nervous system recurrence in HER2-positive breast cancer.
June 5th 2020, 4:35pm
William R. Gwin III, MD, discusses the mechanism of action of alpha-tocopheryloxyacetic acid in HER2-positive metastatic breast cancer.
June 4th 2020, 1:30am
Anne Favret, MD, discusses the importance of clinical trials in the breast cancer space.
